Scarica l'app Stockscreener
1,059.56
3.11%
32.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,027.51
Aprire:
$1032.55
Volume 24 ore:
2.81M
Relative Volume:
0.75
Capitalizzazione di mercato:
$948.93B
Reddito:
$59.42B
Utile/perdita netta:
$18.41B
Rapporto P/E:
52.40
EPS:
20.2197
Flusso di cassa netto:
$6.44B
1 W Prestazione:
+6.20%
1M Prestazione:
+3.34%
6M Prestazione:
+29.31%
1 anno Prestazione:
+34.26%
Intervallo 1D:
$1,032.55
$1,062.41
Intervallo di 1 settimana:
$977.12
$1,062.41
Portata 52W:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,060.23 | 919.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
214.43 | 509.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.18 | 394.69B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
134.51 | 254.37B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.95 | 248.95B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Why Eli Lilly (LLY) Stock Is Trading Up Today - Finviz
Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says - Benzinga
Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says - marketscreener.com
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025 - ts2.tech
Eli Lilly (LLY): B of A Securities Lowers Price Target Despite Buy Rating | LLY Stock News - GuruFocus
Lilly Building $6B Huntsville Pharma Plant - Connect CRE
V. M. Manning & CO. Inc. Invests $875,000 in Eli Lilly and Company $LLY - MarketBeat
Bank of America Has Lowered Expectations for Eli Lilly and Company (NYSE:LLY) Stock Price - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Julie Johnson - MarketBeat
Eli Lilly price target raised to $1,145 from $951 at Goldman Sachs - TipRanks
Eli Lilly and Company $LLY Shares Purchased by NWF Advisory Services Inc. - MarketBeat
Silicon Valley Capital Partners Boosts Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by SevenBridge Financial Group LLC - MarketBeat
Orion Porfolio Solutions LLC Has $39.62 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly & Co: Strategic Initiatives and Promising Market Opportunities Drive Buy Rating - TipRanks
Thrivent Financial for Lutherans Acquires 52,783 Shares of Eli Lilly and Company $LLY - MarketBeat
MASTERINVEST Kapitalanlage GmbH Acquires New Holdings in Eli Lilly and Company $LLY - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Trims Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Just Delivered Fantastic News to Investors - Finviz
Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) (NYSE:LLY) - Seeking Alpha
Cim Investment Management Inc. Has $3.12 Million Stake in Eli Lilly and Company $LLY - MarketBeat
American Trust Buys 3,644 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) Expands Mounjaro Use to Younger Patients in Euro - GuruFocus
Eli Lilly’s Retatrutide Study: A New Hope for CKD Treatment? - TipRanks
Eli Lilly’s New Study on Obesity Drug LY4167586: What Investors Need to Know - TipRanks
Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment - TipRanks
Eli Lilly Completes Phase 1 Study of Eloralintide for Obesity in China - TipRanks
Eli Lilly Weight Loss Drug Shows Impressive Results in Phase 3 Trial - InsideHook
2 Predictions for Novo Nordisk in 2026 - The Motley Fool
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025) - ts2.tech
Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus - MSN
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025) - ts2.tech
Liontrust Investment Partners LLP Grows Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Rexford Capital Inc. Purchases Shares of 1,488 Eli Lilly and Company $LLY - MarketBeat
Public Sector Pension Investment Board Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Castleark Management LLC Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Brick & Kyle Associates Purchases 1,700 Shares of Eli Lilly and Company $LLY - MarketBeat
Advisory Services Network LLC Buys 1,351 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - MSN
Eli Lilly’s Stock Sets a New Industry Standard - AD HOC NEWS
Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far? - simplywall.st
Eli Lilly: The Right Long-Term Strategy - Seeking Alpha
Eli Lilly and Company $LLY is Banque Transatlantique SA's 10th Largest Position - MarketBeat
Blue Capital Inc. Takes Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by AQR Capital Management LLC - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Ameriprise Financial Inc. - MarketBeat
Adage Capital Partners GP L.L.C. Raises Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Further Cements Itself As The King Of Weight Loss (NYSE:LLY) - Seeking Alpha
Why the Market Dipped But Eli Lilly (LLY) Gained Today - sharewise.com
Eli Lilly and Company (NYSE:LLY) Shares Up 1.8%Here's Why - MarketBeat
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next - ts2.tech
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):